
==== Front
BioDrugsBioDrugsBiodrugs1173-88041179-190XSpringer International Publishing Cham 3044384931610.1007/s40259-018-0316-zCorrectionCorrection to: PF-06438179/GP1111: An Infliximab Biosimilar Al-Salama Zaina T. demail@springer.com 0000 0004 0372 1209grid.420067.7Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754 New Zealand 15 11 2018 15 11 2018 2018 32 6 643 643 © Springer Nature 2018Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.issue-copyright-statement© Springer Nature Switzerland AG 2018
==== Body
Correction to: BioDrugs 10.1007/s40259-018-0310-5
The article PF-06438179/GP1111: An Infliximab Biosimilar, written by Zaina T. Al-Salama, was originally published Online First without open access. After publication online, HEXAL AG requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by HEXAL AG. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

